FDC
FDC Limited (FDC) Stock Analysis
FDC Limited is an Indian pharmaceutical company manufacturing APIs and formulations. It markets branded generics in dermatology, ophthalmology, and other therapies in India. The company has a long-established domestic presence. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹330.10
-1.71% 1W | -28.00% 52W
Market Cap
5.4k CR
P/E Ratio
18.4
52W High
₹473.6
52W Low
₹312.9
Div. Yield
3.09%
Beta
0.2
50 DMA
₹352.7
200 DMA
₹374.2
Profit Margin
13.4%
Inst. Own.
7.4%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 536 | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 | 473 | 465 | 585 | 668 |
| Expenses | 414 | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 | 439 | 412 | 478 | 525 |
| Operating Profit | 122 | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 | 34 | 52 | 106 | 143 |
| OPM % | 23% | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% | 7% | 11% | 18% | 21% |
| Other Income | 29 | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 | 21 | 0 | 50 | 48 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 | 15 | 15 | 14 | 15 |
| Profit before tax | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 | 38 | 36 | 140 | 175 |
| Tax % | 22% | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% | 26% | 22% | 26% | 24% |
| Net Profit | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 | 28 | 28 | 103 | 132 |
| EPS in Rs | 6.62 | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 | 1.74 | 1.74 | 6.35 | 8.14 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 888 | 994 | 1,013 | 1,074 | 1,089 | 1,341 | 1,331 | 1,525 | 1,784 | 1,943 | 2,108 | 2,171 | 2,190 |
| Expenses | 690 | 765 | 769 | 841 | 860 | 1,038 | 997 | 1,271 | 1,533 | 1,604 | 1,783 | 1,825 | 1,855 |
| Operating Profit | 199 | 229 | 243 | 233 | 229 | 304 | 334 | 254 | 251 | 339 | 325 | 346 | 335 |
| OPM % | 22% | 23% | 24% | 22% | 21% | 23% | 25% | 17% | 14% | 17% | 15% | 16% | 15% |
| Other Income | 46 | 39 | 44 | 45 | 42 | 57 | 95 | 76 | 50 | 102 | 91 | 93 | 118 |
| Interest | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 |
| Depreciation | 39 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 | 40 | 54 | 59 | 59 |
| Profit before tax | 204 | 232 | 252 | 241 | 237 | 320 | 388 | 289 | 258 | 396 | 357 | 375 | 390 |
| Tax % | 27% | 27% | 25% | 28% | 28% | 25% | 22% | 25% | 25% | 23% | 25% | 25% | |
| Net Profit | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 194 | 305 | 267 | 281 | 293 |
| EPS in Rs | 8.33 | 9.48 | 10.60 | 9.95 | 9.74 | 14.03 | 17.85 | 12.82 | 11.70 | 18.75 | 16.39 | 17.29 | 17.97 |
| Dividend Payout % | 27% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% | 0% | 31% | 29% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 10.0% | 8.0% |
| Profit CAGR | 12.0% | -1.0% | 5.0% |
Shareholding Pattern
Promoters69.66%
FIIs2.41%
DIIs7.17%
Public20.76%
Promoters69.66%
FIIs2.43%
DIIs6.81%
Public21.10%
Promoters69.66%
FIIs2.32%
DIIs6.27%
Public21.76%
Promoters69.65%
FIIs2.40%
DIIs6.29%
Public21.65%
Promoters69.65%
FIIs1.40%
DIIs6.31%
Public22.63%
Promoters69.49%
FIIs3.80%
DIIs8.27%
Public18.44%
Promoters69.66%
FIIs2.65%
DIIs6.94%
Public20.76%
Promoters69.66%
FIIs2.56%
DIIs6.37%
Public21.42%
Promoters69.65%
FIIs2.40%
DIIs6.29%
Public21.65%
Promoters69.65%
FIIs1.40%
DIIs6.31%
Public22.63%
FDC
Holdings Analysis
Key strengths & risk signals
68
Overall
76
Fundamental
60
Technical
Risks (3)
POOR YEAR! Stock declined 28.0% in the last year.
WEAK POSITION! Current price (330.1) is below both moving averages.
WEAK! Trading at 10.7% of 52W range - near yearly lows.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 157,845 vs down days: 123,599. Ratio: 1.28x
TESTING SUPPORT! Stock is at key support level.
Fundamental & Technical Analysis
68Overall
76Fundamental
60Technical
Fundamental Breakdown
Growth Quality
19/30
Revenue CAGR: 6.8% (MODERATE, 8/15). Profit CAGR: 13.2% (GOOD, 11/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.4% profit margin - acceptable profitability.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.39 indicates reasonable valuation.
Dividend Yield
7/10
GOOD DIVIDEND! 3.09% yield - decent income potential.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 19.32% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (352.7) is below 200-day average (374.2) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (330.1) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
1/10
POOR YEAR! Stock declined 28.0% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 157,845 vs down days: 123,599. Ratio: 1.28x
RSI
4/5
APPROACHING OVERSOLD! RSI at 38.7 - watch for reversal.
52W Range
1/5
WEAK! Trading at 10.7% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.7% (1 week), 6.8% (1 month), 23.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDC | ₹330.10 | 18.4 | 13.4% | 6.8% | 13.2% | -28.0% | 68 | BOUNCE FROM SUPPORT | +9.1% | +28.1% | +3.0% | +14.2% |
| NOVARTIND | ₹2,049.00 | 51.7 | 26.4% | -1.4% | -3.4% | +195.7% | 65 | CONSOLIDATING DOWN | +16.7% | +27.8% | +18.5% | +14.6% |
| IOLCP | ₹201.20 | 35.2 | 6.7% | 1.6% | -0.4% | +101.6% | 62 | CONSOLIDATING UP | +90.0% | +21.1% | +37.1% | +22.1% |
| SPARC | ₹185.60 | 3.8 | 83.0% | -45.3% | – | +46.8% | 58 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
| INNOVACAP | ₹1,110.00 | 41.2 | 8.8% | 20.1% | 27.5% | +37.7% | 76 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| BLISSGVS | ₹656.00 | 52.1 | 13.5% | 7.2% | 22.1% | +328.1% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹129.60 | 50.6 | 7.2% | 8.4% | 34.9% | +173.9% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| AARTIPHARM | ₹855.50 | 36.4 | 10.4% | -2.6% | -3.3% | +5.7% | 56 | CONSOLIDATING UP | +65.4% | +24.5% | +38.7% | -8.0% |
Data from TradeAlone · Updated daily
